FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 under
the
Securities Exchange Act of 1934
For the month ended
July, 2013
ICON plc
(Registrant's
name)
0-29714
(Commission file number)
South
County Business Park, Leopardstown, Dublin 18, Ireland
(Address of
principal executive offices)
Brendan Brennan, CFO
South County
Business Park Leopardstown, Dublin 18, Ireland.
Brendan.Brennan@iconplc.com
0011-353-1-291-2000
(Name,
telephone number, email and/or facsmile number and address of Company
contact person)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Yes___X___ No_______
Indicate by check mark whether the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1):
Yes______ No___X___
Indicate by check mark whether the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7):
Yes______ No___X___
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
Yes_______ No___X___
If "Yes" is marked, indicate below the file number assigned to the
registrant in connection with Rule 12g3-2(b):82 N/A
EXHIBIT LIST
Exhibit |
Description |
||
99.1 |
ICON plc Press Release issued July 25, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ICON plc |
||
|
||
Date: |
July 25, 2013 |
/s/ Brendan Brennan |
Brendan Brennan |
||
Chief Financial Officer |
Exhibit 99.1
ICON Reports second quarter 2013 Revenue of $334 million, up 21% year on year, non-GAAP EPS of 43c and raises FY 2013 Guidance.
Highlights – Second Quarter Fiscal 2013.
DUBLIN--(BUSINESS WIRE)--July 25, 2013--ICON plc, (NASDAQ: ICLR), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the second quarter ended June 30, 2013.
Net revenues grew 21% year on year to $334.2 million from $277.0 million in Q2 2012.
Income from operations, excluding restructuring charges of $4.6 million, was $30.9 million or 9.3% of revenue, compared to $16.6 million or 6.0% for the same quarter last year.
Net income, excluding restructuring charges, was $26.5 million or 43 cents per share on a diluted basis, compared with $12.9 million or 21 cents per share last year.
Revenue in the first half of 2013 increased 23% to $651 million from $529 million in 2012.
Income from operations in the first half of 2013, excluding restructuring charges, was $58.3 million or 9.0% of revenue, compared with $28.4m or 5.4% of revenue in the previous year.
Net income, in the first half of 2013, excluding restructuring charges, was $48.7 million or 79 cents per share on a diluted basis, compared with $21.9 million or 36 cents per diluted share last year.
Guidance for the full year 2013 has been updated with revenue expected to be in the range of $1.3 billion - $1.32 billion and EPS guidance in the range of $1.54 - $1.64.
Days sales outstanding, comprising accounts receivable and unbilled revenue less payments on account, were 33 days at June 30, 2013, compared with 40 days at the end of December 2012.
For the quarter ended June 30, 2013, cash generated from operating activities was $10.8 million after expenditure of $26 million on prior period acquisition earn outs and capital expenditure of $7.8 million. The company’s net cash amounted to $184 million at June 30, 2013, compared to net cash of $190 million at December 31, 2012.
During the quarter the company recorded a charge of $4.6 million in relation to various restructuring costs. US GAAP income from operations after these items amounted to $26 million or 7.9% of revenue. US GAAP net income for the quarter was $22 million or 36 cents per share.
CEO Ciaran Murray commented, “I am happy that Q2 was another strong quarter for ICON. We reported revenue growth of 21% year on year and operating margins of 9.3%. We have continued to book satisfactory levels of new business and our trailing twelve month book to bill now stands at 1.3. Consequently we are raising our revenue guidance to the range of $1.3-$1.32 billion and our EPS guidance to the range of $1.54-$1.64 for the financial year 2013.”
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including non-GAAP operating and net income and non-GAAP diluted earnings per share. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.
ICON will hold its second quarter conference call today, July 25, 2013 at 9:00 EST [14:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under “Investors”. This calendar will be updated regularly.
The statements made in this press release may contain forward-looking statements that involve a number of risks and uncertainties. In addition to the matters described in this press release, the ability to maintain large client contracts or enter into new contracts, maintain client relationships and the ability to manage the opening of new offices, the integration of new business mergers and acquisitions, as well as other risks and uncertainties detailed from time to time in reports filed with the US Securities and Exchange Commission by ICON, including its Form 20-F, F-1, S-8 and F-3, may affect the actual results achieved by ICON. ICON disclaims any intent or obligation to update these forward-looking statements.
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 78 locations in 37 countries and has approximately 10,170 employees. Further information is available at www.iconplc.com.
Source: ICON plc
Contact: Investor Relations 1-888-381-7923 or
Brendan Brennan Chief Financial Officer + 353 –1-291-2000 or
Simon Holmes EVP Investor Relations and Corporate Development + 353 –1-291-2000
All at ICON.
ICON/ICLR-F
ICON plc
Consolidated Income Statements (Unaudited)
(Before restructuring and other items)
Three and Six Months ended June 30, 2013 and June 30, 2012
(Dollars, in thousands, except share and per share data)
|
Three Months Ended |
Six Months Ended |
|||||||
|
June 30, |
June 30, | June 30, | June 30, | |||||
|
2013 |
2012 | 2013 | 2012 | |||||
Gross Revenue | 469,626 | 379,620 | 888,685 | 722,675 | |||||
Reimbursable expenses | 135,407 | 102,613 | 237,677 | 193,335 | |||||
Net Revenue | 334,219 | 277,007 | 651,008 | 529,340 | |||||
Costs and expenses | |||||||||
Direct costs | 214,231 | 180,127 | 416,592 | 342,411 | |||||
Selling, general and administrative | 77,548 | 69,410 | 153,112 | 136,925 | |||||
Depreciation and amortization | 11,520 | 10,830 | 22,976 | 21,632 | |||||
Total costs and expenses | 303,299 | 260,367 | 592,680 | 500,968 | |||||
Income from operations | 30,920 | 16,640 | 58,328 | 28,372 | |||||
Net interest expense | (100) | (231) | (285) | (266) | |||||
Income before provision for income taxes | 30,820 | 16,409 | 58,043 | 28,106 | |||||
Provision for income taxes | 4,315 | 3,514 | 9,336 | 6,240 | |||||
Net income | 26,505 | 12,895 | 48,707 | 21,866 | |||||
Net income per ordinary share | |||||||||
Basic | $0.44 | $0.21 | $0.80 | $0.36 | |||||
Diluted | $0.43 | $0.21 | $0.79 | $0.36 | |||||
Weighted average number of ordinary shares | |||||||||
Basic | 60,724,296 | 59,978,509 | 60,555,945 | 60,032,306 | |||||
Diluted | 61,898,903 | 60,630,891 | 61,607,757 | 60,607,635 | |||||
ICON plc
Consolidated Income Statements (Unaudited)
(US GAAP)
Three and Six Months ended June 30, 2013 and June 30, 2012
(Dollars, in thousands, except share and per share data)
|
Three Months Ended |
Six Months Ended |
|||||||
|
June 30, |
June 30, | June 30, | June 30, | |||||
|
2013 |
2012 | 2013 | 2012 | |||||
Gross Revenue | 469,626 | 379,620 | 888,685 | 722,675 | |||||
Reimbursable expenses | 135,407 | 102,613 | 237,677 | 193,335 | |||||
Net Revenue | 334,219 | 277,007 | 651,008 | 529,340 | |||||
Costs and expenses | |||||||||
Direct costs | 214,231 | 180,127 | 416,592 | 342,411 | |||||
Selling, general and administrative | 77,548 | 69,410 | 153,112 | 136,925 | |||||
Depreciation and amortization | 11,520 | 10,830 | 22,976 | 21,632 | |||||
Restructuring and other items | 4,621 | 5,636 | 9,033 | 5,636 | |||||
Total costs and expenses | 307,920 | 266,003 | 601,713 | 506,604 | |||||
Income from operations | 26,299 | 11,004 | 49,295 | 22,736 | |||||
Net interest expense | (100) | (231) | (285) | (266) | |||||
Income before provision for income taxes | 26,199 | 10,773 | 49,010 | 22,470 | |||||
Provision for income taxes | 3,720 | 2,809 | 7,486 | 5,535 | |||||
Net income | 22,479 | 7,964 | 41,524 | 16,935 | |||||
Net income per ordinary share | |||||||||
Basic | $0.37 | $0.13 | $0.69 | $0.28 | |||||
Diluted | $0.36 | $0.13 | $0.67 | $0.28 | |||||
Weighted average number of ordinary shares | |||||||||
Basic | 60,724,296 | 59,978,509 | 60,555,945 | 60,032,306 | |||||
Diluted | 61,898,903 | 60,630,891 | 61,607,757 | 60,607,635 | |||||
ICON plc
Summary Balance Sheet Data
June 30, 2013 and December 31, 2012
(Dollars, in thousands)
June 30, | December 31, | ||||
2013 | 2012 | ||||
(Unaudited) | (Audited) | ||||
Net cash | 183,903 | 190,230 | |||
Accounts receivable | 305,805 | 285,419 | |||
Unbilled revenue | 140,145 | 112,483 | |||
Payments on account | (272,019) | (219,467) | |||
Total | 173,931 | 178,435 | |||
Working Capital | 253,507 | 250,326 | |||
Total Assets | 1,293,122 | 1,202,108 | |||
Shareholder's Equity | 801,708 | 754,575 |
CONTACT:
ICON plc
Investor Relations
1-888-381-7923
or
Brendan
Brennan
CFO
+ 353 1 291 2000
OR
Simon Holmes
EVP IR &
Corporate Development
+3531 291 2000
http://www.iconplc.com